A Multiple Dose Study of LY3023703 in Healthy Participants
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 12/16/2018 |
| Start Date: | May 2013 |
| End Date: | December 2013 |
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3023703 in Healthy Subjects
This is a study of LY3023703 in healthy participants. The purposes of this study are to look
at safety, how well the study drug is tolerated, how much of the study drug gets into the
blood stream and how long it takes the body to remove the study drug. The effects of
LY3023703 on blood pressure after 28 days of dosing will be studied. Information about any
side effects that occur will be collected. The study is expected to last 21 weeks.
at safety, how well the study drug is tolerated, how much of the study drug gets into the
blood stream and how long it takes the body to remove the study drug. The effects of
LY3023703 on blood pressure after 28 days of dosing will be studied. Information about any
side effects that occur will be collected. The study is expected to last 21 weeks.
Inclusion Criteria:
- Overtly healthy individuals based on the history and physical examinations as
determined by the investigator
- Are normotensive (defined as supine systolic blood pressure [BP] less than 140
millimeters of mercury [mm Hg] and diastolic BP less than 90 mm Hg without the use of
any antihypertensives) or results that are judged to be not clinically significant by
the investigator
Exclusion Criteria:
- Have presence of clinically significant active bleeding or history of bleeding
diathesis at the time of screening
- Have presence of active peptic ulcer disease, gastro-intestinal (GI) bleeding, chronic
gastritis, inflammatory bowel disease, or chronic diarrhea
- Have evidence of other chronic liver disease
- Have any use of nonsteroidal anti-inflammatory drugs (NSAIDs), celecoxib, aspirin, or
acetaminophen (at doses greater than 1 gram per day [g/day] within 14 days of
admission
- Have greater than 1 plus pretibial pitting edema or 2 plus ankle or pedal edema
We found this trial at
1
site
Click here to add this to my saved trials
